SLCO1B1 variants and statin-induced myopathy--a genomewide study - PubMed (original) (raw)
Randomized Controlled Trial
. 2008 Aug 21;359(8):789-99.
doi: 10.1056/NEJMoa0801936. Epub 2008 Jul 23.
Collaborators
- PMID: 18650507
- DOI: 10.1056/NEJMoa0801936
Free article
Randomized Controlled Trial
SLCO1B1 variants and statin-induced myopathy--a genomewide study
SEARCH Collaborative Group et al. N Engl J Med. 2008.
Free article
Abstract
Background: Lowering low-density lipoprotein cholesterol with statin therapy results in substantial reductions in cardiovascular events, and larger reductions in cholesterol may produce larger benefits. In rare cases, myopathy occurs in association with statin therapy, especially when the statins are administered at higher doses and with certain other medications.
Methods: We carried out a genomewide association study using approximately 300,000 markers (and additional fine-mapping) in 85 subjects with definite or incipient myopathy and 90 controls, all of whom were taking 80 mg of simvastatin daily as part of a trial involving 12,000 participants. Replication was tested in a trial of 40 mg of simvastatin daily involving 20,000 participants.
Results: The genomewide scan yielded a single strong association of myopathy with the rs4363657 single-nucleotide polymorphism (SNP) located within SLCO1B1 on chromosome 12 (P=4x10(-9)). SLCO1B1 encodes the organic anion-transporting polypeptide OATP1B1, which has been shown to regulate the hepatic uptake of statins. The noncoding rs4363657 SNP was in nearly complete linkage disequilibrium with the nonsynonymous rs4149056 SNP (r(2)=0.97), which has been linked to statin metabolism. The prevalence of the rs4149056 C allele in the population was 15%. The odds ratio for myopathy was 4.5 (95% confidence interval [CI], 2.6 to 7.7) per copy of the C allele, and 16.9 (95% CI, 4.7 to 61.1) in CC as compared with TT homozygotes. More than 60% of these myopathy cases could be attributed to the C variant. The association of rs4149056 with myopathy was replicated in the trial of 40 mg of simvastatin daily, which also showed an association between rs4149056 and the cholesterol-lowering effects of simvastatin. No SNPs in any other region were clearly associated with myopathy.
Conclusions: We have identified common variants in SLCO1B1 that are strongly associated with an increased risk of statin-induced myopathy. Genotyping these variants may help to achieve the benefits of statin therapy more safely and effectively. (Current Controlled Trials number, ISRCTN74348595.)
2008 Massachusetts Medical Society
Comment in
- Pharmacogenomics and drug toxicity.
Nakamura Y. Nakamura Y. N Engl J Med. 2008 Aug 21;359(8):856-8. doi: 10.1056/NEJMe0805136. Epub 2008 Jul 23. N Engl J Med. 2008. PMID: 18650508 No abstract available. - SLCO1B1 variants and statin-induced myopathy.
Vladutiu GD, Isackson PJ. Vladutiu GD, et al. N Engl J Med. 2009 Jan 15;360(3):304. doi: 10.1056/NEJMc081975. N Engl J Med. 2009. PMID: 19144951 No abstract available.
Similar articles
- SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA, Dlouhá D, Adámková V, Zlatohlavek L, Viklický O, Hrubá P, Češka R, Vrablík M. Hubáček JA, et al. Med Sci Monit. 2015 May 20;21:1454-9. doi: 10.12659/MSM.893007. Med Sci Monit. 2015. PMID: 25992810 Free PMC article. - Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.
Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR. Brunham LR, et al. Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18. Pharmacogenomics J. 2012. PMID: 21243006 - [Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy].
Dendramis G. Dendramis G. G Ital Cardiol (Rome). 2011 Mar;12(3):182-5. G Ital Cardiol (Rome). 2011. PMID: 21560474 Review. Italian. - Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case-Control Studies.
Hou Q, Li S, Li L, Li Y, Sun X, Tian H. Hou Q, et al. Medicine (Baltimore). 2015 Sep;94(37):e1268. doi: 10.1097/MD.0000000000001268. Medicine (Baltimore). 2015. PMID: 26376374 Free PMC article. - Association between SLCO1B1 T521C polymorphism and risk of statin-induced myopathy: a meta-analysis.
Xiang Q, Chen SQ, Ma LY, Hu K, Zhang Z, Mu GY, Xie QF, Zhang XD, Cui YM. Xiang Q, et al. Pharmacogenomics J. 2018 Dec;18(6):721-729. doi: 10.1038/s41397-018-0054-0. Epub 2018 Sep 24. Pharmacogenomics J. 2018. PMID: 30250148 Review.
Cited by
- Association of SLCO1B1 gene variants with angiotensin-converting enzyme inhibitor-induced cough in a Pakistani hypertensive cohort.
Sheikh AF, Munawar N, Nawaz R, Khan H, Rafique M, Jahan F, Ahmed S. Sheikh AF, et al. Front Pharmacol. 2024 Sep 4;15:1441251. doi: 10.3389/fphar.2024.1441251. eCollection 2024. Front Pharmacol. 2024. PMID: 39295941 Free PMC article. - Receptor Pharmacogenomics: Deciphering Genetic Influence on Drug Response.
Anghel SA, Dinu-Pirvu CE, Costache MA, Voiculescu AM, Ghica MV, Anuța V, Popa L. Anghel SA, et al. Int J Mol Sci. 2024 Aug 29;25(17):9371. doi: 10.3390/ijms25179371. Int J Mol Sci. 2024. PMID: 39273318 Free PMC article. Review. - Impact of genetic variants in the solute carrier (SLC) genes encoding drug uptake transporters on the response to anticancer chemotherapy.
Marin JJG, Serrano MA, Herraez E, Lozano E, Ortiz-Rivero S, Perez-Silva L, Reviejo M, Briz O. Marin JJG, et al. Cancer Drug Resist. 2024 Jul 18;7:27. doi: 10.20517/cdr.2024.42. eCollection 2024. Cancer Drug Resist. 2024. PMID: 39143954 Free PMC article. Review. - CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association.
Pereira NL, Cresci S, Angiolillo DJ, Batchelor W, Capers Q 4th, Cavallari LH, Leifer D, Luzum JA, Roden DM, Stellos K, Turrise SL, Tuteja S; American Heart Association Professional/Public Education and Publications Committee of the Council on Genomic and Precision Medicine; Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Peripheral Vascular Disease; and Stroke Council. Pereira NL, et al. Circulation. 2024 Aug 6;150(6):e129-e150. doi: 10.1161/CIR.0000000000001257. Epub 2024 Jun 20. Circulation. 2024. PMID: 38899464 Review. - Statins as anti-tumor agents: A paradigm for repurposed drugs.
Tripathi S, Gupta E, Galande S. Tripathi S, et al. Cancer Rep (Hoboken). 2024 May;7(5):e2078. doi: 10.1002/cnr2.2078. Cancer Rep (Hoboken). 2024. PMID: 38711272 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases